Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of patients were able to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback